
New laboratory findings unveiled by Memorial Sloan Kettering Cancer Center (MSK) reveal how tumors carrying BRCA2 genetic mutations survive by relying on a previously unknown backup DNA repair lifeline. While BRCA2 mutations impair a cell’s primary ability to fix double-strand DNA breaks, researchers demonstrated that cancer cells exploit an alternative molecular pathway to keep dividing under therapeutic stress. This discovery clarifies why DNA-damaging chemotherapies like cyclophosphamide succeed in specific clinical settings and provides pharmaceutical researchers with a promising new target to prevent drug resistance in hereditary breast, ovarian, and prostate cancers.